Survival benefit of Boron neutron capture therapy for recurrent malignant gliomas

Shin Ichi Miyatake, Shinji Kawabata, Kunio Yokoyama, Toshihiko Kuroiwa, Hiroyuki Michiue, Yoshinori Sakurai, Hiroaki Kumada, Minoru Suzuki, Akira Maruhashi, Mitsunori Kirihata, Koji Ono

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

We have applied boron neutron capture therapy (BNCT) to malignant brain tumors. Here we evaluated the survival benefit of BNCT for recurrent malignant glioma (MG). Since 2002, we have treated 22 cases of recurrent MG with BNCT. Survival time was analyzed with special reference to recursive partitioning analysis (RPA) classification, by Carson et al. (J Clin Oncol 25:2601-2606, 2007). Median survival times (MSTs) after BNCT for all patients and for glioblastoma as on-study histology at recurrence was 10.8 months (n = 22; 95% CI, 7.3-12.8 months) and 9.6 months (n = 19; 95% CI, 6.9-11.4 months), respectively. In our study, MST for the high-risk RPA classes was 9.1 months (n = 11; 95% CI, 4.4-11.0 months). By contrast, the original journal data showed that the MST of the same RPA classes was 4.4 months (n = 129; 95% CI, 3.6-5.4 months). BNCT showed a survival benefit for recurrent MG, especially in the high-risk group.

Original languageEnglish
Pages (from-to)199-206
Number of pages8
JournalJournal of neuro-oncology
Volume91
Issue number2
DOIs
Publication statusPublished - Jan 1 2009

    Fingerprint

Keywords

  • BNCT
  • BPA-PET
  • GBM
  • MG
  • RPA

ASJC Scopus subject areas

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Cite this

Miyatake, S. I., Kawabata, S., Yokoyama, K., Kuroiwa, T., Michiue, H., Sakurai, Y., Kumada, H., Suzuki, M., Maruhashi, A., Kirihata, M., & Ono, K. (2009). Survival benefit of Boron neutron capture therapy for recurrent malignant gliomas. Journal of neuro-oncology, 91(2), 199-206. https://doi.org/10.1007/s11060-008-9699-x